Compositions and methods for selective inhibition of nicotine acetylcholine receptors
US8980923B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Jun 18, 2012 |
| Grant date | Mar 17, 2015 |
| Priority date | — |
| Expiry date | Jun 18, 2032 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P25/34
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention concerns methods for treating or preventing neurological disorders characterized by dysfunction of nicotinic acetylcholine receptors by administering 2,2,6,6-tetramethylpiperidin-4-yl heptanoate (TMPH), or a pharmaceutically acceptable salt thereof, to the patient. In another aspect, the present invention pertains to pharmaceutical compositions containing TMPH, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier. In another aspect, the present invention pertains to methods for selectively inhibiting nicotinic acetylcholine receptors that lack an α5, α6, or β3 subunit by contacting an effective amount of TMPH, or a pharmaceutically acceptable salt thereof, to the receptor. The method for selectively inhibiting nicotinic acethylcholine receptors that lack an α5 subunit can be carried out in vivo or in vitro.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.